US 12,115,200 B2
Lactic acid bacteria and use thereof
Dong-Hyun Kim, Seoul (KR); and Myung Joo Han, Seoul (KR)
Appl. No. 17/290,516
Filed by UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, Gyeonggi-do (KR); and NAVIPHARM CO.,LTD., Gyeonggi-do (KR)
PCT Filed Apr. 30, 2019, PCT No. PCT/KR2019/005239
§ 371(c)(1), (2) Date Apr. 30, 2021,
PCT Pub. No. WO2020/091166, PCT Pub. Date May 7, 2020.
Claims priority of application No. 1020180132834 (KR), filed on Nov. 1, 2018.
Prior Publication US 2023/0181657 A1, Jun. 15, 2023
Int. Cl. A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61P 3/04 (2006.01); A61P 19/10 (2006.01); A61P 25/24 (2006.01); C12N 1/20 (2006.01); A61K 35/00 (2006.01); C12R 1/25 (2006.01)
CPC A61K 35/745 (2013.01) [A61K 35/747 (2013.01); A61P 3/04 (2018.01); A61P 19/10 (2018.01); A61P 25/24 (2018.01); C12N 1/20 (2013.01); A61K 2035/115 (2013.01); C12R 2001/25 (2021.05)] 8 Claims
OG exemplary drawing
 
1. A method for treating a female menopausal disorder comprising administering to a subject in need thereof an effective amount of Bifidobacterium longum NK49 having the accession number KCCM12088P,
wherein the subject is a female having a sign of loss of female reproductive function, and
wherein the female menopausal disorder is at least one selected from the group consisting of depression, anxiety, obesity, and osteoporosis.